



PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Xermelo Prior Authorization Policy

- Xermelo™ (telotristat ethyl tablets – Lexicon)

REVIEW DATE: 05/15/2024

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Xermelo, an inhibitor of tryptophan hydroxylase, is indicated for the treatment of **carcinoid syndrome diarrhea** in combination with somatostatin analog therapy in adults inadequately controlled by somatostatin analog therapy.¹

The efficacy of Xermelo was evaluated in patients with metastatic neuroendocrine tumor and carcinoid syndrome diarrhea who were having between 4 to 12 daily bowel movements despite the use of somatostatin analog therapy at a stable dose for at least 3 months.¹

Guidelines

The National Comprehensive Cancer Network (NCCN) guidelines for treatment of neuroendocrine and adrenal tumors (version 1.2023 – August 2, 2023) state that Xermelo can be considered in combination with long-acting somatostatin analog (e.g. Sandostatin® LAR Depot [octreotide subcutaneous injection] or Somatuline® Depot [lanreotide subcutaneous injection]) for persistent diarrhea due to poorly controlled carcinoid syndrome.²

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Xermelo. All approvals are provided for the duration noted below.

• **Xermelo™ (telotristat ethyl tablets – Lexicon)**
is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indication

1. Carcinoid Syndrome Diarrhea. Approve for 1 year if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve if the patient meets ALL of the following (i, ii, and iii):

i. Patient has been on a long-acting somatostatin analog therapy for at least 3 consecutive months; AND

Note: Examples of long-acting somatostatin analog therapy are Somatuline Depot (lanreotide subcutaneous injection) and Sandostatin LAR Depot (octreotide subcutaneous injection).

ii. While on a long-acting somatostatin analog therapy (prior to starting Xermelo), the patient continues to have at least four bowel movements per day; AND

iii. Xermelo will be used concomitantly with a long-acting somatostatin analog therapy.

B) Patient is Currently Receiving Xermelo. Approve if the patient is continuing to take Xermelo concomitantly with a long-acting somatostatin analog therapy for carcinoid syndrome diarrhea.

CONDITIONS NOT COVERED

Xermelo™ (telotristat ethyl tablets – Lexicon)
is(are) considered experimental, investigational or unproven for ANY other use(s)

REFERENCES

1. Xermelo™ tablets [prescribing information]. The Woodlands, TX: Merck; September 2022.
2. The NCCN Neuroendocrine and Adrenal Tumors Clinical Practice Guidelines in Oncology (version 1.2023 – August 2, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on May 13, 2024.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	06/14/2023
Annual Revision	No criteria changes.	05/15/2024

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.